Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

In a terrifying twist, Lost star Evangeline Lilly reveals she suffered major brain damage after falling face-first onto a boulder, RadarOnline.com can reveal. The 46-year-old actress smashed up her ...

Evangeline Lilly recently revealed the financial and emotional toll of her recovery following a traumatic brain injury. In a candid Instagram post, she stated, “I have spent a lot of money getting ...

Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co. Currently Novo sells the drug in plastic ...

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

EVANGELINE PARISH, La. (KLFY) — Ville Platte activist Rufus Searile has been arrested in Evangeline Parish and is now facing multiple sex crime charges involving a minor. Sheriff Charles Guillory ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

CORPUS CHRISTI, Texas — Corpus Christi’s push to secure more water from the Evangeline Aquifer has hit a major roadblock. City leaders learned they will not receive drilling permits by the February 6 ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...